Uncommon Neurological Comorbidity: A Patient with Myasthenia Gravis and Epilepsy. A Case Report

Authors

DOI:

https://doi.org/10.14748/aqm33k90

Keywords:

myasthenia gravis

Abstract

Myasthenia gravis (MG) is a rare autoimmune disorder characterized by an antibody-mediated neuromuscular transmission block, leading to skeletal muscle weakness and fatigue. Epilepsy, a condition of unprovoked, recurrent seizures, rarely coexists with MG. Recent studies indicate an elevated epilepsy risk in patients with autoimmune diseases, including MG, potentially linked to autoimmune mechanisms or long-term anticonvulsant use.

We report a 73-year-old woman diagnosed with MG, treated with pyridostigmine, with complaints of difficulty swallowing, excessive salivation, drooping eyelids, increased fatigue in the arms and legs, and with three generalized tonic-clonic (GTC) seizures in the past year, each lasting 1–2 minutes. The most recent seizure occurred a week before hospitalization. Neurological examination revealed bilateral ptosis, increased limb fatigue, and dysphagia. Electromyography (EMG) confirmed postsynaptic neuromuscular damage consistent with MG. electroencephalography (EEG) demonstrated epileptiform activity.

This case highlights the rare but clinically significant coexistence of MG and epilepsy, emphasizing the need for thorough neurological assessment in MG patients with seizure-like episodes. Recognizing epilepsy in MG is crucial for appropriate treatment and improved patient outcomes. Further research is needed on autoimmune comorbidities in neurological disorders.

Author Biographies

  • Bora Dogan, Medical University of Varna

    Student, Faculty of Medicine

  • Emran Lyutfi, Medical University of Varna

    First Neurology Clinic, St. Marina University Hospital

  • Borislav Ivanov, Medical University of Varna

    Department of Clinical Medical Sciences, Faculty of Dental Medicine

  • Ara Kaprelyan, Medical University of Varna

    First Neurology Clinic, St. Marina University Hospital

References

[1] Asenova A, Bozhinova V, Alexandrova I. Juvenile myasthenia gravis – Diagnosis and treatment part 2; 2018. (in Bulgarian).

[2] Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015 Oct;14(10):1023-36. doi: 10.1016/S1474-4422(15)00145-3. DOI: https://doi.org/10.1016/S1474-4422(15)00145-3

[3] Ong MS, Kohane IS, Cai T, Gorman MP, Mandl KD. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol. 2014 May;71(5):569-74. doi: 10.1001/jamaneurol.2014.188. DOI: https://doi.org/10.1001/jamaneurol.2014.188

[4] Milanov I, Zakhariev Z, Bozhinova V, editors. National Consensus On The Diagnosis And Treatment Of Epilepsy. 2023. Available from: http://www.nevrologiabg.com/wp-content/uploads/2020/09/Consensus_BG.pdf. (in Bulgarian).

[5] Su JJ, Chiu MJ, Chang YC. Coexistence of Epilepsy and Myasthenia Gravis: Report of Four Patients and Review of the Literature, Acta Neurol Taiwan. 2003;12:181-6.

[6] Oyarzun I, Hernández G, Sala-Padró J, Morandeira F, Casasnovas C, Falip M. Epilepsy and Myasthenia Gravis: A Case Series. Brain Sci. 2024 Aug 28;14(9):870. doi: 10.3390/brainsci14090870. DOI: https://doi.org/10.3390/brainsci14090870

[7] Amanat M, Thijs RD, Salehi M, Sander JW. Seizures as a clinical manifestation in somatic autoimmune disorders. Seizure. 2019 Jan;64:59-64. doi: 10.1016/j.seizure.2018.11.012. DOI: https://doi.org/10.1016/j.seizure.2018.11.012

[8] Lorenzoni PJ, Ducci RD, Tensini TS, Dalledone G, Kay CSK, de Paola L, et al. Treatment of epilepsy in patients with myasthenia gravis: Is really harder than it looks? J Clin Neurosci. 2017 Oct;44:353-6. doi: 10.1016/j.jocn.2017.06.067. DOI: https://doi.org/10.1016/j.jocn.2017.06.067

[9] Morren JA, Li Y. Myasthenia gravis: Frequently asked questions. Cleve Clin J Med. 2023 Feb 1;90(2):103-113. doi: 10.3949/ccjm.90a.22017. DOI: https://doi.org/10.3949/ccjm.90a.22017

[10] Kaminski HJ, Sikorski P, Coronel SI, Kusner LL. Myasthenia gravis: the future is here. J Clin Invest. 2024 Jun 17;134(12):e179742. doi: 10.1172/JCI179742. DOI: https://doi.org/10.1172/JCI179742

[11] Estephan EP, Baima JPS, Zambon AA. Myasthenia gravis in clinical practice. Arq Neuropsiquiatr. 2022 May;80(5 Suppl 1):257-265. doi: 10.1590/0004-282X-ANP-2022-S105. DOI: https://doi.org/10.1590/0004-282x-anp-2022-s105

[12] Sánchez-Villalobos JM, Villegas-Martínez I, Pérez-Vicente JA. A Well-Tolerated and Effective Antiepileptic Drug for Patients With Myasthenia Gravis at Last?. Clin Neuropharmacol. 2018;41(2):80-1. doi:10.1097/WNF.0000000000000267. DOI: https://doi.org/10.1097/WNF.0000000000000267

Downloads

Published

2025-04-10

Issue

Section

Case Reports

How to Cite

Uncommon Neurological Comorbidity: A Patient with Myasthenia Gravis and Epilepsy. A Case Report. (2025). Scripta Scientifica Medica, 57(1), 54-57. https://doi.org/10.14748/aqm33k90